



DEC - 2020 Q3.

(Rs' mn)



- PURCHASE OF CONVERTIBLE BONDS.

$60,000 \times Rs.10,000 = 600$ / 8% P.A / 3YR

CAN BE CONVERTED TO O/S AT

$60/2$ PER SHARE = $\frac{600}{60} = 10$ mn SHARES.

PRICE IS IN THE MONEY.

$\frac{10mn}{(75mn + 10mn)} \times 100\% = 11.76\%$
 CROISSANCE O/S

| NA | COMPANY |
|----------------------------|-------------------|
| SLC - | 1,485 |
| FCR - | 440 |
| R/E - | 1,850 |
| | <u>3,775</u> |
| PV ADJ | |
| FAVOURABLE LEASE (375-250) | +125 |
| DI - 125 x 28% | (35) |
| | <u>3,865</u> (10) |

$$75000 \times 45\% = \frac{33.75}{85} = \underline{\underline{39.71\%}}$$

$$\underline{\underline{51.47\%}}$$


$$\frac{10 + 39.75}{85} \times 100\% = \underline{\underline{51.47\%}}$$

WCT AT FV

$$75000 \times 55\% \times Rs. 53 = \underline{\underline{2,186.25}} \text{ (9)}$$

FV OF EXISTING INVESTMENT

$$75000 \times 35\% \times Rs. 53 = \underline{\underline{1,391.25}}$$




WCT AT FV

$$50000 \times 49\% \times Rs. 75 = \underline{\underline{61.25}} \text{ (13)}$$

| NA | |
|-------|------------------------|
| s/c - | 50 |
| r/t - | 63 |
| r/l - | 10 |
| | <u><u>123</u></u> (14) |


FANOURABLE LEASE





REDUNDANCY — NOT RECOGNIZED ON 30/9/2020.

GROUP STRUCTURE.



| COMPANY | € / 14% | WGT % |
|---------|-------------------------|-------|
| IACD | 45% + CONV. BONDS | 55% |
| HCL | 24% + (60% x 45%) = 51% | 49% ✓ |

"CONTROL" — POWER OVER RELEVANT ACTIVITIES.
 + EXPOSURE TO VARIABLE RETURNS.
 + ABSOLUTE WFT POWER TO INFLUENCE RETURNS.

... RELEVANT ACTIVITIES ...

ABILITY TO APPOINT MAJORITY OF BOD → CONTROL

ACQUIRE MAJORITY (VOTING RIGHTS) OR CONTRACTUAL ARRANGEMENT

EXISTING = 35% + 10% = 45%

+ POTENTIAL VOTING RIGHTS (CONVERTIBLE BONDS)

51.47%

CONSIDER ONLY IF VOTING RIGHTS ARE SUBSTANTIVE ✓

YES

EXERCISABLE ✓

OPTIONS ARE IN THE MONEY

- OPTION PRICE < FV → IN THE MONEY
- " > FV → OUT OF THE MONEY

CONSOLIDATION WORKING

| | Investment and Associates | GW - IASB | NIIF - IASB | GW - IASB | NIIF - IASB | RIF | FCFR |
|-----------------------|---------------------------|-----------|-------------|-----------|-------------|-------|------|
| Inv - 1/12/19 ① | 984.5 | | | | | | |
| GBP - ② | 201.3 | | | | | 201.3 | |
| FCFR - 1/12/19-2019 ③ | 42.7 | | | | | | 42.7 |
| RIF - ④ | 96.95 | | | | | 96.95 | |
| BAL - 30/9/2020 | 1325.45 | | | | | | |
| FX risk expense ⑤ | (1.22545) | | | | | | |

INVT
 - 75mm x 35% x 53

TRP TO PRL - PCTE

NEW INVT

- CASH (6)

- SHARE ISSUE (7)

- CONVERSIONS PAPER (8)

1,391.25
 35%

+65.8
 +42.7 (42.7)

250

105

78.88

10%

✓ NCST AS PV (9)

NA - 30/9/2020 (10)

GW - 30/9/2020

2,186.25

2,186.25

(3865)

146.38

INVT - BY HCL (11)

- BY HCD - BALANCE

$\frac{55}{80\%} \times 60\% = 41.25$
 (12)

30

[55%]
 (22.69)
 DR

[45%]
 18.56
 DR

NCST OF HCL (13)

NA OF HCL - (14)

GBP


61.25
 DR

61.25
 CR

(123)

(13.19)
 DR

+13.19
 DR



POST ACC² PAT OF HCD AS AN ASSOCIATE

| Group | 1/12/19 | | 30/9/2020 |
|-------|---------|-------|-----------|
| FCTR | 322 | + 122 | 444 |
| R/E | 1,581 | + 277 | 1,858 |

FCTR PORTION TO HCL = $122 \times 35\% = 42.7$ (3)

R/E " " " = $277 \times 35\% = 96.95$ (4)

